1,405 results match your criteria Melanoma Iris

Trans-Scleral Cyclophotocoagulation in Refractory Pigment Dispersion-Like Glaucoma Secondary to Ciliary Body Melanoma.

J Curr Ophthalmol 2022 Jan-Mar;34(1):118-120. Epub 2022 Apr 16.

Eye Research Center, The Five Senses Institute, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.

Purpose: To report a case of ciliary body melanoma with acute high intraocular pressure (IOP) due to pigment dispersion, treated by limited trans-scleral cyclophotocoagulation (TSCPC) and plaque radiotherapy.

Methods: A 33-year-old woman was referred to clinic with acute ocular pain and decreased visual acuity from 1 week before presentation. The IOP was 55 mmHg accompanied by red eye, perilimbal injection, mild corneal edema (stromal and epithelial), scattered pigment dust on central corneal endothelium, 4 anterior chamber pigments, and pigmented cells. Read More

View Article and Full-Text PDF

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.

J Immunother Cancer 2022 05;10(5)

Drug Development Department, Gustave Roussy Institute, Villejuif, France.

Background: This phase 1b study (NCT02323191) evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of colony-stimulating factor-1 receptor-blocking monoclonal antibody (mAb) emactuzumab in combination with the programmed cell death-1 ligand (PD-L1)-blocking mAb atezolizumab in patients with advanced solid tumors naïve or experienced for immune checkpoint blockers (ICBs).

Methods: Emactuzumab (500-1350 mg flat) and atezolizumab (1200 mg flat) were administered intravenously every 3 weeks. Dose escalation of emactuzumab was conducted using the 3+3 design up to the maximum tolerated dose (MTD) or optimal biological dose (OBD). Read More

View Article and Full-Text PDF

Surgical Approach in Intraocular Tumors

Turk J Ophthalmol 2022 04;52(2):125-138

Ankara University Faculty of Medicine, Department of Ophthalmology, Ankara, Turkey

Surgery in intraocular tumors is done for excision/biopsy and the management of complications secondary to the treatment of these tumors. Excision/biopsy of intraocular tumors can be done via fine-needle aspiration biopsy (FNAB), transretinal biopsy (TRB), partial lamellar sclerouvectomy (PLSU), and endoresection. FNAB, TRB, and PLSU can be used in tumors that cannot be diagnosed by clinical examination and other ancillary testing methods. Read More

View Article and Full-Text PDF

Population-based incidence of intraocular tumours in Olmsted County, Minnesota.

Br J Ophthalmol 2022 Apr 21. Epub 2022 Apr 21.

Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA

Background/aims: To determine population-based incidence of intraocular tumours in Olmsted County, Minnesota.

Methods: Record review of the Rochester Epidemiology Project medical record linkage system from 1 January 2006 to 31 December 2015 for patient demographics, tumour type by clinical diagnosis and presence or absence of confirmation by histopathology. The incidence rate of any intraocular tumour and of each tumour type was calculated per million person-years. Read More

View Article and Full-Text PDF

Endocapsular artificial iris implantation for iris defects: Reducing symptoms, restoring visual function and improving cosmesis.

Clin Exp Ophthalmol 2022 Apr 14. Epub 2022 Apr 14.

Department of Ophthalmology, New Zealand National Eye Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.

Background: To investigate repair of iris defects by endocapsular implantation of an artificial iris, in relation to visual outcomes, safety profile and patient satisfaction.

Methods: Retrospective, consecutive case series from Greenlane tertiary teaching hospital and Eye Institute, Auckland, New Zealand. Medical records of patients implanted with an endocapsular artificial iris were reviewed and followed for minimum 3 months. Read More

View Article and Full-Text PDF

Dynamic observation: Immune-privileged microenvironment limited the effectiveness of immunotherapy in an intraocular metastasis mouse model.

Ophthalmic Res 2022 Apr 8. Epub 2022 Apr 8.

Introduction: Intraocular metastasis (IM) occurred in approximately 8-10% of patients with metastatic malignancy, for whom oncological immunotherapies showed poor visual potential. However, the mechanism for that inefficiency remains unclear and requires further exploration.

Methods: we established a novel mouse model of intraocular metastasis by intracarotid injection of cutaneous melanoma cells. Read More

View Article and Full-Text PDF

Iris melanoma: factors predictive of post-management secondary glaucoma in 271 cases at a Single Ocular Oncology Centre.

Eye (Lond) 2022 Apr 5. Epub 2022 Apr 5.

Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, 19107, USA.

Background/aims: To identify factors predictive of post-management secondary glaucoma in eyes with iris melanoma.

Methods: Patients with iris melanoma who were conservatively managed on the Ocular Oncology Service, Wills Eye Hospital from 1970 to 2016 were included. Charts were retrospectively reviewed, and binary logistic regression analysis was performed. Read More

View Article and Full-Text PDF

Iris melanocytic tumours in New Zealand/Aotearoa: presentation, management and outcome in a high UV exposure environment.

Eye (Lond) 2022 Mar 25. Epub 2022 Mar 25.

Department of Ophthalmology, New Zealand National Eye Centre, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Background/objectives: Iris melanoma, a rare intraocular malignancy, represents the smallest subgroup of uveal melanoma. This first, comprehensive study of iris melanocytic lesions in the high ultraviolet environment in New Zealand/ Aotearoa (NZ) examines diagnosis, management and outcomes.

Subjects/methods: Retrospective study of iris melanocytic tumours referred to tertiary referral centres in Auckland, NZ, over 20 years (1999-2018). Read More

View Article and Full-Text PDF

Clinical Outcomes after Surgical Resection Combined with Brachytherapy for Uveal Melanomas.

J Clin Med 2022 Mar 15;11(6). Epub 2022 Mar 15.

Department of Radio Physics, Virgen Macarena University Hospital, 41009 Seville, Spain.

Currently, brachytherapy is the most commonly used therapeutic approach for uveal melanomas. Surgical resection by means of endoresection or exoresection is an alternative approach. The present report recounts our experience over 15 years in the treatment of uveal melanoma using a combined approach of resection surgery with brachytherapy. Read More

View Article and Full-Text PDF

Bioengineered Platelets Combining Chemotherapy and Immunotherapy for Postsurgical Melanoma Treatment: Internal Core-Loaded Doxorubicin and External Surface-Anchored Anti-PD-L1 Antibody Backpacks.

Nano Lett 2022 04 23;22(7):3141-3150. Epub 2022 Mar 23.

Multi-Scale Robotics Lab (MSRL), Institute of Robotics & Intelligent Systems (IRIS), ETH Zurich, Zurich 8092, Switzerland.

The pivotal factors affecting the survival rate of patients include metastasis and tumor recurrence after the resection of the primary tumor. Anti-PD-L1 antibody (aPD-L1) has promising efficacy but with some side effects for the off-target binding between aPD-L1 and normal tissues. Here, inspired by the excellent targeting capability of platelets with respect to tumor cells, we propose bioengineered platelets (PDNGs) with inner-loaded doxorubicin (DOX) and outer-anchored aPD-L1-cross-linked nanogels to reduce tumor relapse and metastatic spread postoperation. Read More

View Article and Full-Text PDF

Metastatic tumours to the eye. Review of metastasis to the iris, ciliary body, choroid, retina, optic disc, vitreous, and/or lens capsule.

Eye (Lond) 2022 Mar 19. Epub 2022 Mar 19.

Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA.

Metastasis to the eye can involve the choroid (90%), ciliary body (2%), iris (8%), and retina, optic disc, vitreous, and/or lens capsule (<1-4%). The mean number of uveal metastasis per eye (1.7), mean tumour base (11. Read More

View Article and Full-Text PDF

The long-term prognosis of patients with untreated primary uveal melanoma: A systematic review and meta-analysis.

Crit Rev Oncol Hematol 2022 Apr 15;172:103652. Epub 2022 Mar 15.

Department of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska Institutet, Tomtebodavägen 18A, plan 5, 171 77 Stockholm, Sweden; Department of Pathology, Västmanland Hospital Västerås, Västerås, Sweden.

Purpose: To examine patient survival in untreated primary uveal melanoma.

Methods: Systematic review and meta-analysis.

Results: Seven studies with a total of 19 patients were included. Read More

View Article and Full-Text PDF

Feline Uveal Melanoma Review: Our Current Understanding and Recent Research Advances.

Vet Sci 2022 Jan 26;9(2). Epub 2022 Jan 26.

The Ophthalmology Department, The University of Edinburgh Hospital for Small Animals (HfSA), Royal (Dick) School of Veterinary Studies (R(D)SVS), Easter Bush Campus, Midlothian EH25 9RG, UK.

Melanocytic neoplasia is the most common form of ocular tumour in cats, accounting for 67% of cases in an analysis of 2614 cases of primary ocular neoplasia. Feline diffuse iris melanoma (FDIM) is by far the most common form of ocular melanocytic neoplasia, with limbal melanomas and atypical melanoma (melanoma affecting the choroid or ciliary body) infrequently recognised. Early lesions begin as flat areas of pigmentation of the iris, known as iris melanosis. Read More

View Article and Full-Text PDF
January 2022

Inhibition of post-surgery tumour recurrence via a sprayable chemo-immunotherapy gel releasing PD-L1 antibody and platelet-derived small EVs.

J Nanobiotechnology 2022 Feb 2;20(1):62. Epub 2022 Feb 2.

Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, 110016, Liaoning, People's Republic of China.

Background: Melanoma is the most serious type of skin cancer, and surgery is an effective method to treat melanoma. Unfortunately, local residual micro-infiltrated tumour cells and systemic circulating tumour cells (CTCs) are significant causes of treatment failure, leading to tumour recurrence and metastasis.

Methods: Small EVs were isolated from platelets by differential centrifugation, and doxorubicin-loaded small EVs (PexD) was prepared by mixing small EVs with doxorubicin (DOX). Read More

View Article and Full-Text PDF
February 2022

The unfolded protein response and the biology of uveal melanoma.

Biochimie 2022 Jun 29;197:9-18. Epub 2022 Jan 29.

Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, 2006, Australia. Electronic address:

Uveal melanoma (UM) is a highly metastatic ocular cancer that arises from the melanocytes of the uveal tract (the choroid, ciliary body and iris). Despite a growing understanding of UM biology, effective systemic treatments are currently lacking and the cancer has an extremely poor prognosis. Therefore, identifying novel agents that act by new tumorigenic mechanisms in UM is essential to address this unmet clinical need. Read More

View Article and Full-Text PDF

Iris melanoma with ciliary body infiltration presenting as a presumed chronic unilateral inflammatory glaucoma. The challenges of iris tumor biopsy assessment.

Pol J Pathol 2021 ;72(3):267-271

Department of Ophthalmology, Poznan University of Medical Sciences, Poznan, Poland.

Uveal melanoma is the most common primary malignancy of the eye in adults. It may involve the choroid and ciliary body, and in only 2-3% of cases it involves the iris. We present a case of a 56-year-old patient with a 6-year history of unilateral, inflammatory, refractory glaucoma of the right eye. Read More

View Article and Full-Text PDF
January 2022

Proton beam radiation for iris melanoma: case series and review of literature.

BMJ Open Ophthalmol 2021 23;6(1):e000683. Epub 2021 Dec 23.

Department of Opthalmology, Essen University Hospital, Essen, Germany.

Objective: Purpose of this study is to analyse the visual outcomes, the complication and eye retention rate as well as tumour control data of patients treated with proton beam radiation therapy (PBRT) for iris melanoma.

Methods: Retrospective case series and review based on patients' records. All tumours were categorised according to the American Joint Committee of Cancer staging criteria for primary iris melanoma und underwent either sectorial or whole anterior segment PBRT. Read More

View Article and Full-Text PDF
December 2021

New Perspectives for Eye-Sparing Treatment Strategies in Primary Uveal Melanoma.

Cancers (Basel) 2021 Dec 28;14(1). Epub 2021 Dec 28.

Small Animal Magnetic Resonance Imaging Laboratory, Mossakowski Medical Research Institute, Polish Academy of Sciences, 02-106 Warsaw, Poland.

Uveal melanoma is the most common intraocular malignancy and arises from melanocytes in the choroid, ciliary body, or iris. The current eye-sparing treatment options include surgical treatment, plaque brachytherapy, proton beam radiotherapy, stereotactic photon radiotherapy, or photodynamic therapy. However, the efficacy of these methods is still unsatisfactory. Read More

View Article and Full-Text PDF
December 2021

Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions.

Cancers (Basel) 2021 Dec 25;14(1). Epub 2021 Dec 25.

Laboratory of Clinical and Experimental Pathology, Université Côte d'Azur, Pasteur Hospital, Centre Hospitalier Universitaire de Nice, Biobank BB-0033-00025, 06000 Nice, France.

Uveal melanoma (UM) is the most common malignant intraocular tumour in the adult population. It is a rare cancer with an incidence of nearly five cases per million inhabitants per year, which develops from the uncontrolled proliferation of melanocytes in the choroid (≈90%), ciliary body (≈6%) or iris (≈4%). Patients initially present either with symptoms like blurred vision or photopsia, or without symptoms, with the tumour being detected in routine eye exams. Read More

View Article and Full-Text PDF
December 2021

Treatment of Uveal Melanoma With Radioactive Iodine 125 Implant Compared With Proton Beam Radiotherapy.

Mayo Clin Proc Innov Qual Outcomes 2022 Feb 22;6(1):27-36. Epub 2021 Dec 22.

Department of Radiation Oncology, Emory University Proton Therapy Center, Winship Cancer Institute, Atlanta, GA.

Objective: To review the current state of radiation therapy for uveal melanoma and compare particle radiation and brachytherapy.

Patients And Methods: The medical records of 156 patients treated for uveal melanoma between May 30, 2012, and March 16, 2020, were retrospectively reviewed. Treatments consisted of either radioactive iodine 125 implant (RAI) or fractionated proton radiation (proton beam therapy [PBT]). Read More

View Article and Full-Text PDF
February 2022

Topography and clinical features of iris melanoma.

BMC Ophthalmol 2022 Jan 3;22(1). Epub 2022 Jan 3.

Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway.

Background: To characterise the topographical and clinical features of primary iris melanoma and to visualise the patterns of tumour extent in the iris.

Methods: Clinical characteristics of iris melanomas were analysed, and data on their size, shape, and location were converted into a database of two-dimensional iris charts by means of computer-drawing software. The geometric centre of each tumour was entered into corresponding sectors of the chart. Read More

View Article and Full-Text PDF
January 2022

Case Series: Different Presentations of Iris Melanoma-Potential Masquerade of Benign and Malignant.

Optom Vis Sci 2022 03;99(3):298-302

Department of Ophthalmology, New Zealand National Eye Centre, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.

Significance: Iris melanoma and iris nevi can be challenging to distinguish clinically. This case series provides unique insight into the rare condition and variable clinical presentations of iris melanoma.

Purpose: This study aimed to highlight the varying clinical presentations of iris melanoma and to demonstrate the overlapping features of melanoma and nevi. Read More

View Article and Full-Text PDF

Proton beam therapy followed by pembrolizumab for giant ocular surface conjunctival malignant melanoma: A case report.

Mol Clin Oncol 2022 Jan 18;16(1):12. Epub 2021 Nov 18.

Department of Radiology, Tsuyama Chuo Hospital, Tsuyama, Okayama 708-0841, Japan.

The present study describes proton beam therapy as a clinical option to achieve local control of giant conjunctival melanoma in an aged person, instead of orbital exenteration. An 80-year-old woman with one-year history of left-eye injection and hemorrhage experienced rapid growth of the ocular surface black mass. At the initial visit, a black, elastic hard, hemorrhage-prone, thickened mass in the size of 30x40 mm with a presumed wide stalk covered the total area of the lid fissure on the left side. Read More

View Article and Full-Text PDF
January 2022

No differences in the long-term prognosis of iris and choroidal melanomas when adjusting for tumor thickness and diameter.

BMC Cancer 2021 Nov 24;21(1):1270. Epub 2021 Nov 24.

St. Erik Eye Hospital, Eugeniavägen 12, 17164, Stockholm, Sweden.

Objective: To assess the long-term prognosis for patients with iris melanomas and compare it with the prognosis for small choroidal melanomas.

Design: Retrospective observational case series.

Methods: All patients treated for iris melanomas at a single referral institution between January 1st 1986 and January 1st 2016 were included. Read More

View Article and Full-Text PDF
November 2021

Chromosome 3 and 8q Aberrations in Uveal Melanoma Show Greater Impact on Survival in Patients with Light Iris versus Dark Iris Color.

Ophthalmology 2022 04 13;129(4):421-430. Epub 2021 Nov 13.

Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands. Electronic address:

Purpose: Individuals with gray, blue, or green eyes have a higher chance of developing uveal melanoma (UM) than those with brown eyes. We wondered whether iris pigmentation might be related not only to predisposition to UM but also to its behavior; therefore, we compared the clinical, histopathologic, and genetic characteristics of UM between eyes with different colors.

Design: We determined iris color in a large cohort of patients enucleated for UM. Read More

View Article and Full-Text PDF

Uveal melanoma incidentally diagnosed with neuroimaging, a case series of 3 patients.

Radiol Case Rep 2022 Jan 2;17(1):54-59. Epub 2021 Nov 2.

Department of Ophthalmology, University of Washington, 325 Ninth Ave, Box 356421, Seattle, WA 98104, USA.

Uveal melanoma is the most common primary intraocular malignancy and can occur in the choroid, the ciliary body, or the iris. It is most often diagnosed based on clinical examination by an ophthalmologist. Nearly all patients present with visual symptoms. Read More

View Article and Full-Text PDF
January 2022

Tumor-infiltrating lymphocytes (TILs) in feline melanocytic tumors: A preliminary investigation.

Vet Immunol Immunopathol 2021 Dec 18;242:110337. Epub 2021 Oct 18.

Department of Veterinary Medicine, University of Perugia, Via San Costanzo, 4, 06126, Perugia, Italy.

The presence and the role of tumor-infiltrating lymphocytes (TILs) in different types of tumors, but particularly in melanoma, has become more and more investigated during the last decade, both in human and veterinary medicine. Melanocytic tumors are quite rare in cats, with diffuse iris melanoma being the most commonly diagnosed in this species. The aim of this study was to characterize the lymphocytic infiltration in feline melanocytic tumors and to analyze their association with the histological features of malignancy recognized in these tumors, as well as with the expression of the most commonly used immunohistochemical markers. Read More

View Article and Full-Text PDF
December 2021

Uveal melanoma diagnosis and current treatment options (Review).

Exp Ther Med 2021 Dec 11;22(6):1428. Epub 2021 Oct 11.

Department of Ophthalmology, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.

Uveal melanoma is a rare condition accounting for only 5% of all primary melanoma cases. Still, it is the most frequently diagnosed primary intraocular malignant tumor in adults. Almost 90% of the tumors involve the choroid and only a small percentage affects the ciliary body or the iris. Read More

View Article and Full-Text PDF
December 2021

Documented Growth of Presumed Iris Tapioca Nevus to Tapioca Melanoma.

Ophthalmology 2021 11;128(11):1626

Ocular Oncology Service, Moorfields Eye Hospital, London, United Kingdom; Retinoblastoma Service, Royal London Hospital, London, United Kingdom; NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital and University College London Institute of Ophthalmology, London, United Kingdom.

View Article and Full-Text PDF
November 2021

Iris Melanoma in a Patient with Retinitis Pigmentosa.

Ocul Oncol Pathol 2021 Sep 27;7(4):267-271. Epub 2021 May 27.

Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan.

This report describes the histopathological findings of an iris melanoma that developed in a patient with retinitis pigmentosa (RP). A 66-year-old man was referred to our hospital with a diagnosis of iris tumor. He had a medical history of RP for over 25 years. Read More

View Article and Full-Text PDF
September 2021